ATE226830T1 - Verfahren und zusammensetzung zur verbesserten parenteralen ernährung - Google Patents

Verfahren und zusammensetzung zur verbesserten parenteralen ernährung

Info

Publication number
ATE226830T1
ATE226830T1 AT96929722T AT96929722T ATE226830T1 AT E226830 T1 ATE226830 T1 AT E226830T1 AT 96929722 T AT96929722 T AT 96929722T AT 96929722 T AT96929722 T AT 96929722T AT E226830 T1 ATE226830 T1 AT E226830T1
Authority
AT
Austria
Prior art keywords
composition
parenteral nutrition
nutrients
improved
improved parenteral
Prior art date
Application number
AT96929722T
Other languages
English (en)
Inventor
Michael A Oberarzt Mediz Nauck
Bochum Knapps Ruhr-Universitat
Fred W Wagner
Original Assignee
Bionebraska Inc
Nauck Michael A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionebraska Inc, Nauck Michael A filed Critical Bionebraska Inc
Application granted granted Critical
Publication of ATE226830T1 publication Critical patent/ATE226830T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96929722T 1995-08-22 1996-08-22 Verfahren und zusammensetzung zur verbesserten parenteralen ernährung ATE226830T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19530865A DE19530865A1 (de) 1995-08-22 1995-08-22 Wirkstoff sowie Mittel zur parenteralen Ernährung
PCT/US1996/013615 WO1997007814A1 (en) 1995-08-22 1996-08-22 Method and composition for enhanced parenteral nutrition

Publications (1)

Publication Number Publication Date
ATE226830T1 true ATE226830T1 (de) 2002-11-15

Family

ID=7770095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929722T ATE226830T1 (de) 1995-08-22 1996-08-22 Verfahren und zusammensetzung zur verbesserten parenteralen ernährung

Country Status (12)

Country Link
EP (1) EP0851763B1 (de)
JP (1) JP3839485B2 (de)
CN (2) CN100374155C (de)
AT (1) ATE226830T1 (de)
AU (1) AU723383B2 (de)
CA (1) CA2227278A1 (de)
CZ (1) CZ50898A3 (de)
DE (2) DE19530865A1 (de)
DK (1) DK0851763T3 (de)
HU (1) HUP9903534A3 (de)
PL (1) PL191022B1 (de)
WO (1) WO1997007814A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003066084A1 (en) * 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
MX2007005521A (es) * 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US7691424B2 (en) * 2005-10-28 2010-04-06 T.F.H. Pulications, Inc. Nutritional supplement
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2443146B1 (de) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip-rezeptor-aktive glucagon-verbindungen
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
EP2588126A4 (de) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp Amidbasierte glucagon-superfamilien-peptid-prodrugs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
WO2016180353A1 (zh) * 2015-05-13 2016-11-17 杭州九源基因工程有限公司 一种包含glp-1类似物的药物制剂及其制备方法
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
EP0617626A1 (de) * 1991-12-18 1994-10-05 Pfizer Inc. Sojabohnen protein oder hydrolyzate in pharmazeutische zusammensetzungen zum schützen bioaktiver peptide gegenüber enzymatische inaktivierung
JP3061316B2 (ja) * 1992-01-29 2000-07-10 雪印乳業株式会社 乳酸菌が腸管に定着しやすい発酵乳及び乳酸菌飲料
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JPH08268908A (ja) * 1995-03-29 1996-10-15 Green Cross Corp:The 消化管粘膜機能維持剤

Also Published As

Publication number Publication date
PL325117A1 (en) 1998-07-06
EP0851763A1 (de) 1998-07-08
CN1541708A (zh) 2004-11-03
JP3839485B2 (ja) 2006-11-01
WO1997007814A1 (en) 1997-03-06
AU6900696A (en) 1997-03-19
PL191022B1 (pl) 2006-03-31
JPH11514972A (ja) 1999-12-21
DE19530865A1 (de) 1997-02-27
AU723383B2 (en) 2000-08-24
CN1145497C (zh) 2004-04-14
CN100374155C (zh) 2008-03-12
DK0851763T3 (da) 2003-03-03
HUP9903534A2 (hu) 2000-03-28
HUP9903534A3 (en) 2000-04-28
DE69624580D1 (de) 2002-12-05
EP0851763B1 (de) 2002-10-30
CN1195992A (zh) 1998-10-14
CA2227278A1 (en) 1997-03-06
DE69624580T2 (de) 2004-04-22
CZ50898A3 (cs) 1999-01-13

Similar Documents

Publication Publication Date Title
ATE226830T1 (de) Verfahren und zusammensetzung zur verbesserten parenteralen ernährung
AU693371B2 (en) Multimedia playing apparatus utilizing synchronization of scenario-defined processing time points with playing of finite-time monomedia item
HU9402238D0 (en) 1-benzenesulfonyl-1,3-dihydro-2h-benzimidazol-2-one derivatives, process for producing them and pharmaceutical compositions containing them
HUP9900728A3 (en) Peptide derivatives as thrombin inhibitors, process for producing them and pharmaceutical compositions containing them
HUT46365A (en) Process for producing glycopeptide antibiotics and pharmaceutical compositions comprising the same
HUP9802857A3 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors, process for producing them and pharmaceutical compositions containing them
AU7294796A (en) Nutritional support of paediatric patients
HU9301054D0 (en) Method for producing cyclopeptides and pharmaceutical preparatives containing them
HUT52775A (en) Process for producing spiro-isoquinoline-pyrrolidine-tetrones, theyr analogues anf pharmaceutical compositions containing them
AU3533389A (en) Method and apparatus for peeling crustaceans
HU902505D0 (en) Process for producing dipeptide derivatives of enzyme blocking effect and pharmaceutical preparatives containing them
GR880300151T1 (en) Derivative of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it
EP0635218A4 (de) Verfahren zur geschmacksmodifizierung und verfahren zur verminderung eines bitteren geschmack.
EP0520987A4 (de) Methode zur appetitzügelung durch verabreichung von tetrahydro-g(b)-carbolinderivaten.
AU5435990A (en) Monoclonal antibodies to human glutathione s transferase pi
AU5981596A (en) Method and system for obtaining target infusion dosage
HUT44035A (en) Process for producing new antibiotic bbm-1675 c and d of antitumor effect and pharmaceutical preparations containing these
AU6700490A (en) Method and apparatus for adjusting fuel injection timing
AU4836790A (en) Pdgf-a, pdgf-aa, pdgf-ab, process for producing them and drugs containing them
AU5505990A (en) Polysaccharide mixture with immune stimulating and antiproliferating effect, method of production and medicines containing the substances
IL90187A0 (en) Method for treating an auto-immune disease using succinyl-acetone and pharmaceutical compositions containing the same
PL292414A1 (en) Method of obtaining complexes containing s-(+)-phenylalcanic and -hydroxyalcanic acids
AU4566689A (en) Method for bauxite treatment
AU2469088A (en) Pharmaceutical composition for the parenteral administration of navelbine
AU2769189A (en) Method for timing pulses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0851763

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee